Novartis To Launch Bayer MS Therapy In 2009 To Build Market Presence
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with Bayer Schering aims to bolster Novartis’ presence ahead of a potential launch of FTY720, an oral multiple sclerosis treatment.
You may also be interested in...
New Brand, Same MS Drug: Novartis Launches Extavia In Europe
Novartis lays foundation for potential MS platform with European launch of its own branded version of Bayer-Schering’s Betaferon (interferon beta-1b).
New Brand, Same MS Drug: Novartis Launches Extavia In Europe
Novartis lays foundation for potential MS platform with European launch of its own branded version of Bayer-Schering’s Betaferon (interferon beta-1b).
Race To Develop Oral MS Therapy Heats Up As Novartis Releases Data Results
In Phase II studies, 77% of patients treated with Novartis' FTY720 remained relapse free after two years.